This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Fresenius Set for Global Expansion of Research Activities
by Zacks Equity Research
Fresenius Medical Care (FMS) aims to expand the scope of its clinical research activities through an integration move.
Cara Shares Up on Positive Phase III Data for Itchiness Drug
by Zacks Equity Research
Cara (CARA) reports positive top-line data from phase III study of Korsuva injection in hemodialysis patients with moderate-to-severe chronic kidney disease-related pruritus.
Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Fresenius Medical (FMS) gains from solid international revenues in Q1.
Fresenius Medical to Make Huge Investments, Competition Rife
by Zacks Equity Research
Fresenius Medical (FMS) is likely to make huge investments in India and China.
Fresenius Medical's New Hemodialysis Software Gets FDA Nod
by Zacks Equity Research
Fresenius Medical (FMS) offers a wide range of HD and PD dialysis products.
Baxter's (BAX) New Tie Up to Boost Acute Therapies Business
by Zacks Equity Research
Baxter's (BAX) Acute Therapies business is expected to grow 7-8% in 2019.
Should Value Investors Pick Fresenius Medical (FMS) Stock?
by Zacks Equity Research
Let's see if Fresenius Medical (FMS) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Fresenius Medical (FMS) Earnings Beat, Revenues Miss in Q4
by Zacks Equity Research
Fresenius Medical (FMS) sees higher Q4 revenues in EMEA and Asia Pacific regions.
New Strong Sell Stocks for January 16th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for January 9th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Baxter's PD Solution to Treat Patients, Prospects Bright
by Zacks Equity Research
Baxter's (BAX) kidney care portfolio likely to favor the company as kidney care demand shoots up in the United States.
Cara (CARA) Up on IDMC's Recommendation to Continue Trial
by Zacks Equity Research
Cara (CARA) gains after IDMC recommended the late-stage trial on lead drug, Korsuva, to continue without any modifications.
Fresenius Medical (FMS) Beats on Q3 Earnings, Lags Revenues
by Zacks Equity Research
Lower North America sales hurt Fresenius Medical's (FMS) Q3 results. Care Coordination margin improves significantly.
Kidney Care Demand Shoots Up in US: 3 Stocks Likely to Gain
by Sreyoshi Mukherjee
As the U.S. dialysis industry has been garnering huge profits for decades, some dialysis stocks are worth a look.
Fresenius Medical (FMS) Misses Q2 Earnings & Sales Estimates
by Zacks Equity Research
Lower peritoneal dialysis sales in Q2 hurt Fresenius Medical (FMS); solid geographical performance encourages.
Here's Why You Should Steer Clear of Fresenius Medical Now
by Zacks Equity Research
Soft segmental performance and a downbeat revenue guidance reflect Fresenius Medical's (FMS) weaknesses.
Here's Why You Should Sell Fresenius Medical (FMS) Stock Now
by Zacks Equity Research
A rapidly changing healthcare environment in the United States, sluggish Q1 and competition in the niche markets are major headwinds for Fresenius Medical (FMS).
Fresenius Medical (FMS) Misses on Q1 Earnings, Lowers View
by Zacks Equity Research
Lackluster performance in North America and foreign exchange headwinds mar Fresenius Medical's (FMS) bottom line in Q1.
3 Reasons Why You Should Invest in Baxter International Now
by Zacks Equity Research
Baxter (BAX) gains ground on strategic buyouts and a raised guidance for 2018.
The Zacks Analyst Blog Highlights: ArcelorMittal, Fresenius Medical Care AG, Orion Engineered Carbons S.A., Royal Dutch Shell and Globant S.A.
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ArcelorMittal, Fresenius Medical Care AG, Orion Engineered Carbons S.A., Royal Dutch Shell and Globant S.A.
ECB Sticks to Accommodative Monetary Stance: 5 Top Picks
by Nalak Das
The ECB kept its main refinancing rate, and rates on marginal lending facility and deposit facility at unchanged at 0%, 0.258% and -0.4%, respectively.
IMF Raises Its Growth Forecast for Germany: 4 Top Picks
by Nitish Marwah
IMF's recent forecast on Germany's economic growth and encouraging comments from the country's finance ministry indicate its resilience to the recent economic cooldown.
Global Growth to Hit 7-Year High, Says IMF: 5 Picks
by Swarup Gupta
Projections for growth in the United States, Britain and Eurozone have experienced an upward revision.
Here's Why You Should Invest in Fresenius Medical Right Now
by Zacks Equity Research
Fresenius Medical (FMS) receives a boost from solid guidance, higher geographical revenues and strategic acquisitions.
3 Reasons Why You Should Invest in Fresenius Medical Now
by Zacks Equity Research
Wide range of dialysis products, deliberate initiatives to gain market traction and solid international foothold are major catalysts for Fresenius Medical (FMS) at the moment.